


Amendments to the claims:

This listing of claims will replace all previous versions, and listings, of claims in this application.

Listing of Claims:

Claim 1 (previously presented) A pharmaceutical composition comprising a compound of formula I



wherein n is 0;

m is 1;

p is 0;

Y is CH, N or NO

X is oxygen;

W is two H moieties;

A is C(R²);

G is C(R³);

D is C(R⁴);

Y is N;

R¹ is hydrogen or C₁-C₄ alkyl;

R², R³, and R⁴ are independently hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, aryl, heteroaryl, OH, OC₁-C₄ alkyl, CO₂R¹, -CN, -NO₂, -NR⁵R⁶, -CF₃, -OSO₂CF₃, or R² and R³, or R³ and R⁴, respectively, may together form another six membered aromatic ring sharing A and G, or G and D, respectively, and substituted with one to two of the following substituents: independently hydrogen, halogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, aryl, heteroaryl, OH, OC₁-C₄ alkyl, CO₂R¹, -CN, -NO₂, -NR⁵R⁶, -CF₃, OSO₂CF₃;

R⁵ and R⁶ are independently hydrogen, C₁-C₄ alkyl, C(O)R⁷, C(O)NHR⁸, C(O)OR⁹, SO₂R¹⁰ or may together be (CH₂)_kQ(CH₂)_k where Q is O, S, NR¹¹, or a bond;

j is 2 to 7;

k is 0 to 2;

R⁷, R⁸, R⁹, R¹⁰, and R¹¹ are independently C₁-C₄ alkyl, aryl, or heteroaryl;
together with at least one inert pharmaceutically acceptable diluent or carrier.

Claim 2 (previously presented) A pharmaceutical composition according to Claim 1,
comprising a compound selected from:

spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-bromospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-phenylspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-nitrospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
1'-chlorospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]isoquinoline];
5'-(phenylcarboxamido)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-(phenylaminocarbonylamino)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-(phenylsulfonylamido)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-N-methylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-N,N-dimethylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-N,N-diethylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-N-ethylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-N-benzylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-N-formamidospino[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-N-acetamidospino[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]isoquinoline];
spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]quinoline];
5'-ethenylspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-(E)-(phenylethenyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-(4-morpholino)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-(1-azetidiny)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

5'-(E)-(2-(4-pyridyl)ethenyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-(E)-(2-(2-pyridyl)ethenyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-(2-trimethylsilylethynyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-ethynylspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-(2-furyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-(3-pyridyl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-methylspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine-5' carbonitrile];
spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine-5' carboxamide];
5'-N'-(3-chlorophenyl)ureidoaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-N'-(2-nitrophenyl)ureidoaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
4'-chlorospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
4'-methoxyspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
4'-phenylthiospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
4'-(N-2-aminoethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
4'-Phenylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
4'-methylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
4'-(4-N-methylpiperazin-1-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
4-chloro-spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[3,2-c]pyridine];
spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[3,2-c]pyridine];
6'-fluorospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine-6'-carbonitrile], and
6'-chlorospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
or an enantiomer, or a pharmaceutically acceptable salt thereof.

Claim 3 (previously presented) A pharmaceutical composition according to Claim 1,
comprising a compound selected from:

5'-bromospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-phenylspiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-nitrospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
5'-aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]isoquinoline];
spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]quinoline];
spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine], and
spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine-5'carboxamide];
or an enantiomer, or a pharmaceutically acceptable salt thereof.

Claim 4 (original) A pharmaceutical composition according to Claim 1, comprising
(2'R)-spiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];
or a pharmaceutically acceptable salt thereof.

Claim 5 (original) A pharmaceutical composition according to Claim 1, comprising less than
80% by weight of said compound of formula I in admixture with an inert pharmaceutically
acceptable diluent or carrier.

Claim 6 (original) A pharmaceutical composition according to Claim 1, comprising less than
50% by weight of said compound of formula I in admixture with an inert pharmaceutically
acceptable diluent or carrier.

Claim 7 (original) A pharmaceutical composition according to Claim 1, wherein said at least
one inert pharmaceutically acceptable diluent or carrier is selected from lactose, starch, talc,
stearic acid, tartaric acid, water, alcohols, glycerin, vegetable oils and natural or hardened oils or
waxes.

Claim 8 (previously presented) A pharmaceutical composition according to Claim 1, wherein said composition is formulated as:

 a tablet or dragee and wherein said at least one inert pharmaceutically acceptable diluent or carrier is selected from lactose, starch, talc, stearic acid;

 a capsules wherein said at least one inert pharmaceutically acceptable diluent or carrier is selected from tartaric acid or lactose; or

 an injectable solution wherein said at least one inert pharmaceutically acceptable diluent or carrier is selected from water, alcohols, glycerin, vegetable oils; or

 a suppository wherein said at least one inert pharmaceutically acceptable diluent or carrier is selected from natural or hardened oils or waxes.

Claim 9 - 17 (cancelled)

Claim 18 (original) A method for inducing the cessation of smoking, or for the treatment or prophylaxis of nicotine addiction comprising administering a pharmaceutical composition according to Claim 1.

Claim 19 (previously presented) A process for the preparation of a pharmaceutical composition according to Claim 1 which comprises mixing:

 a compound of formula I, or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, in an amount to provide less than about 80% by weight of said compound with at least one inert pharmaceutically acceptable diluent or carrier selected from lactose, starch, talc, stearic acid or tartaric acid.

Claim 20 (previously presented) A process according to Claim 19 comprising mixing a compound of formula I, or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, in an amount to provide less than about 50% by weight of said compound with at least one inert pharmaceutically acceptable diluent or carrier selected from lactose, starch, talc, stearic acid or tartaric acid.